These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39093590)

  • 1. Prescription Fills for Semaglutide Products by Payment Method.
    Scannell C; Romley J; Myerson R; Goldman D; Qato DM
    JAMA Health Forum; 2024 Aug; 5(8):e242026. PubMed ID: 39093590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
    Chaitoff A; Bendicksen L; Feldman WB; Zheutlin AR; Lalani HS
    Ann Intern Med; 2024 Oct; 177(10):1440-1442. PubMed ID: 39186788
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 4. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
    Semenya AM; Wilson SA
    Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
    [No Abstract]   [Full Text] [Related]  

  • 7. Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
    Mahase E
    BMJ; 2024 Aug; 386():q1878. PubMed ID: 39197936
    [No Abstract]   [Full Text] [Related]  

  • 8. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 10. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
    Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
    Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 14. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
    Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
    Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
    Cui J; Klepser DG; McAdam-Marx C
    J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.
    Ashraf AR; Mackey TK; Schmidt J; Kulcsár G; Vida RG; Li J; Fittler A
    JAMA Netw Open; 2024 Aug; 7(8):e2428280. PubMed ID: 39093567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral semaglutide (Rybelsus) for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
    [No Abstract]   [Full Text] [Related]  

  • 20. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.